Analysis of Binding of KIR3DS1*014 to HLA Suggests Distinct Evolutionary History of KIR3DS1

Geraldine M. O'Connor, Eriko Yamada, Andy Rampersaud, Rasmi Thomas, Mary Carrington and Daniel W. McVicar

*J Immunol* 2011; 187:2162-2171; Prepublished online 29 July 2011; doi: 10.4049/jimmunol.1002906

http://www.jimmunol.org/content/187/5/2162

---

**References**
This article cites 37 articles, 21 of which you can access for free at:
http://www.jimmunol.org/content/187/5/2162.full#ref-list-1

**Subscription**
Information about subscribing to *The Journal of Immunology* is online at:
http://jimmunol.org/subscription

**Permissions**
Submit copyright permission requests at:
http://www.aai.org/About/Publications/JI/copyright.html

**Email Alerts**
Receive free email-alerts when new articles cite this article. Sign up at:
http://jimmunol.org/alerts
Analysis of Binding of KIR3DS1*014 to HLA Suggests Distinct Evolutionary History of KIR3DS1

Geraldine M. O’Connor,* Eriko Yamada,* Andy Rampersaud,* Rasmie Thomas,†‡ and Daniel W. McVicar*

NK cell activity is regulated by the integration of positive and negative signals. One important source of these signals for human NK cells is the killer Ig-like receptor (KIR) family, which includes both members that transduce positive and those that generate negative signals. KIR3DL1 inhibits NK cell activity upon engagement by its ligand HLA-Bw4. The highly homologous KIR3DS1 is an activating receptor, which is implicated in the outcome of a variety of pathological situations. However, unlike KIR3DL1, direct binding of KIR3DS1* cells to HLA has not been demonstrated. We analyzed four key amino acid differences between KIR3DL1*01502 and KIR3DS1*013 to determine their role in KIR binding to HLA. Single substitutions of these residues dramatically reduced binding by KIR3DL1. In the reciprocal experiment, we found that the rare KIR3DS1 allotype KIR3DS1*014 binds HLA-Bw4 even though it differs from KIR3DS1*013 at only one of these positions (position 138). This reactivity was unexpectedly dependent on residues at other variable positions, as HLA-Bw4 binding was lost in receptors with KIR3DL1-like residues at both positions 199 and 138. These data provide the first evidence, to our knowledge, for the direct binding of KIR3DS1+ cells to HLA-Bw4 and high the key role for position 138 in determining ligand specificity of KIR3DS1. They also reveal that KIR3DS1 reactivity and specificity is dictated by complex interactions between the residues in this region, suggesting a unique functional evolution of KIR3DS1 within the activating KIR family. The Journal of Immunology, 2011, 187: 2162–2171.

The killer Ig-like receptor (KIR) family of NK receptors consists of 14 members including receptors with both inhibitory and activating potential (1). This family shows a high degree of variation among populations, including variation in gene content, at the level of allelic polymorphism and in the frequency and level of expression (2–4). Several of the KIRs are known to bind to HLA class I molecules. KIR2DL1 and KIR2DL2/3 recognize HLA-C2 and -C1, respectively (5), KIR3DL2 recognizes A*3 and A*11 allotypes (6), KIR2DL4 is reported to bind to HLA-G (7), and KIR3DL1 recognizes HLA-A or -B molecules expressing the Bw4 epitope (8). Activating members of the KIR family, which show a high degree of sequence similarity to inhibitory members in the extracellular portion, also bind to HLA, albeit with much lower affinity (9–11).

Recognition of HLA-Bw4 by KIR3DL1 allotypes is well characterized, with sequence variation in the KIR3DL1 molecule, the Bw4 molecule, and the sequence of peptide presented by the Bw4 molecule all influencing the interaction (12–15). There is also growing evidence that KIR3DS1 may recognize HLA-Bw4. Several genetic studies have correlated the presence of both KIR3DS1 and HLA-Bw4 with the outcome of disease (16). In particular in HIV infection, it has been shown that the epistatic interaction of KIR3DS1 and a subgroup of Bw4 carrying isoleucine at position 80 (Bw4-80I) delays progression to AIDS, reducing viral load early as well as leading to a reduction in opportunistic infections later in disease (17, 18). Functional evidence to support the interaction of KIR3DS1 and HLA-Bw4, at least in the context of HIV infection, comes from the report that KIR3DS1+ NK cells can suppress HIV replication and lyse HIV+ target cells in a Bw4-dependent manner (19). However, several attempts to characterize the direct interaction of KIR3DS1 with Bw4 have been unsuccessful—traditional Bw4+ target cell lines are not killed in a KIR3DS1-dependent manner, and HLA-Bw4 tetramers do not bind to KIR3DS1-expressing cells, even those tetramers that present HIV-derived peptides (13, 20, 21).

The highly polymorphic KIR3DL1 gene locus is unique in the KIR family in encoding both inhibitory (KIR3DL1) and activating (KIR3DS1) allotypes. The 3D KIRs contain three extracellular Ig domains termed D0 (membrane distal), D1, and D2 (membrane proximal). Each of these domains is encoded by a separate exon, exons 3, 4, and 5, respectively of the KIR3DL1 gene (22). The D1 and D2 domains of KIR3DL1 are homologous to the two Ig domains of type I 2D KIRs (2DL1, 2, and 3), which contain a D1 and D2 but have a pseudoexon in place of exon 3. Type II 2D KIRs (2DL4 and 2DL5) contain a D0 and D2 configuration. The structure of the interaction of type I 2D KIRs with their HLA-C ligands has been resolved and shown to be dependent on residues from both D1 and D2 (23). Although no structure of a 3D KIR either alone or in association with HLA has been resolved, a sequence comparison with the D1 and D2 domains of KIR3DL1 suggests that many of the predicted residues for 2D KIR are preserved in the apparent interaction of KIR3DL1 with Bw4 (23). The role of D0 is even less well defined, but this domain has been
shown to be necessary in the binding of KIR3DL1 to HLA-B*5101 (24). A recent model of the interaction of KIR3DL1 with HLA-Bw4 proposes that D0 combines with D1 and D2 to form the binding interface, with D0 making direct contact with the HLA molecule (25).

Allotypic polymorphism of KIR3DL1 leads to variation in the cell surface staining phenotype with two specific anti-KIR3DL1 Ab clones: DX9 and Z27. Initially, this was described as some allotypes (including *005) giving a low-intensity staining pattern with both Abs, whereas others (including *01502) give a high-intensity pattern (26). However, as more allotypes have been described, it has become clear that different allotypes show a broad range of Ab staining levels. Evidence suggests that these differences are a reflection of the level of receptor expressed at the cell surface rather than variation in Ab affinity (27). In one extreme case, the common *004 allotype, which folds poorly, is completely retained intracellularly (28). The KIR3DS1 allotype is not recognized by the DX9 clone but gives a very low intensity staining pattern with Z27 (13, 29). Both DX9 and Z27 Abs can prevent binding of KIR3DL1 to its Bw4 ligand, suggesting an overlap between the Ab epitope and the HLA binding site.

KIR3DL1*054 is a recently described allotype of KIR3DL1, which shows a pattern of amino acid substitutions in the D1 domain not seen in other inhibitory allotypes but present in the activating KIR3DS1 (2). As the D1 domain is believed to contribute to both the HLA binding face and the Ab recognition of these molecules, we wished to address the role of the amino acids shared between *054 and KIR3DS1 in the regulation of expression levels and in the recognition of HLA. Delineating the role of these variable positions in the binding capacity of these receptors will allow us to understand better the functional consequences of KIR3DL1 polymorphism and, perhaps more importantly, will provide insight into the specific requirements of KIR3DS1 for HLA recognition, which to date has proved elusive.

Materials and Methods

Site-directed mutagenesis of KIR3DL1*01502 and KIR3DS1*013

FLAG-tagged (N-terminal) KIR3DL1*01502 or KIR3DS1*013 (referred to in this article as KIR3DS1) sequences were cloned into the pEF Six5-HisTOPO vector. The transmembrane domain of KIR3DS1 was modified to mirror that of KIR3DL1, negating the need for DAP12 association. These sequences were then mutated using the QuickChange Site-Directed Mutagenesis Kit (Stratagene) according to the manufacturer’s instructions using the primers outlined in Table I.

To generate double mutants, mutated constructs were used as template with primers for mutation of the second position as outlined above except in the case of KIR3DS1 S163P + R166L where, due to the small distance between the residues, a second set of primers was used. The full coding sequence of the resulting plasmids was sequenced to confirm the mutations.

Analysis of KIR3DL1 expression on HEK293T cell lines

HEK293T cells were transfected as previously described (2) using plasmids containing full-length KIR3DL1*01502, KIR3DL1*054, KIR3DS1, or mutants thereof. Expression of the KIR on transfected cells was analyzed by mAb staining using FITC-conjugated anti-FLAG (Sigma), PE-conjugated anti-KIR3DL1 mAb clone DX9 (BioLegend), or clone Z27 (Beckman Coulter) and analyzed on a BD FACScan. All experiments included staining with isotype control Abs to permit accurate positioning of electronic gates for analysis of KIR3DL1 expression.

Analysis of HLA tetramer binding to KIR

The following tetramers were obtained through the National Institutes of Health Tetracer Facility: B*0801+ fold with FLKQEQGL (from HIV nef), A*2402+ fold with RYPLTFGW (from HIV nef), B*2705+ fold with SRHHAFLFR (from human aggrcan), B*5701 tetramer fold with TSTLQEQQIGW (from HIV gag) was a kind gift from Dr. Galit Alter (Harvard Medical School, Boston, MA).

PE-conjugated HLA tetramers were incubated with transfected cell lines for 30 min at 4°C prior to washing and analysis on a BD FACScan. For blocking experiments, cells were preincubated with unconjugated Z27 Ab (10 μg/ml; Beckman Coulter) or mouse IgG1 (10 μg/ml; Sigma) for 10 min at 4°C prior to staining with HLA tetramers. Integrity of the HLA tetramers was verified by staining of a leukocyte Ig-like receptor subfamily B member 1 (LILRB1)-transfected Ba/F3 cell line (data not shown).

KIR3DS1 reporter assay

Stable Jurkat cell lines expressing the extracellular domain of KIR3DS1 fused to the CD3 7-chain were used in an NFAT reporter assay as described in Ref. 13. A reporter cell line for KIR3DS1*014 was generated by mutating KIR3DS1 using the primer pair outlined in Table I and stimulated with plate-bound Z27 Ab, the HLA class I deficient 721.221 cell line, or HLA-B*5701 and HLA-B*5801 transfectants. Lysates were harvested, and luciferase activity was measured using Promega’s Dual-Luciferase Reporter Assay System according to the manufacturer’s instructions. Luciferase activity was normalized relative to unstimulated controls.

Results

Novel allelic variant of KIR3DL1 is poorly recognized by two anti-3DL1 Abs despite maintained cell surface expression

The recently described KIR3DL1 allotype *054 is identical to the highly expressed KIR3DL1*002 allotype except for the D1 domain, encoded by exon 4, where it is identical to KIR3DS1 (Fig. 1A). We have recently described that an HIV* + donor expressing this rare allotype gives a very-low-intensity staining profile with the DX9 Ab (2). This is possibly a reflection of reduced cell surface expression, poor Ab affinity, or a consequence of viral infection. To examine the cell surface expression and Ab affinity of this KIR3DL1 allotype, we transfected HEK293T cells with a construct consisting of the N-terminal FLAG-tagged *054 sequence. These cells were then stained with the anti-KIR3DL1 Abs DX9 and Z27 and with anti-FLAG and compared with the profile observed for another highly expressed KIR3DL1 allotype, *01502, which has an additional variation at position 238 (Fig. 1A). The intensity of FLAG staining observed with the *054 construct was comparable with that seen with the highly expressed *01502 allotype confirming that the *054 allotype is well expressed at the cell surface (Fig. 1B, 1C). However, staining with both Z27 and DX9 Abs was much dimmer than that seen with the *01502 allotype, indicating that although both these Abs recognize *054, they do so with reduced affinity. Thus, whereas variation in Ab staining for other allotypes of KIR3DL1 has been ascribed to variation in cell surface expression, in the case of *054 reduced intensity of Ab staining is a reflection of reduced affinity of both anti-3DL1 Abs for this allotype.

The recognition of KIR3DS1 by Z27 also results in a very low-intensity staining pattern, whereas this allotype is not recognized by DX9. Although it has been suggested that this is due to reduced Ab recognition, and not low expression of KIR3DS1, this has not been formally addressed. To examine this, we compared the intensity of FLAG staining of HEK293T cells transfected with FLAG-tagged KIR3DS1 and KIR3DL1*01502 constructs. We found no difference in the level of FLAG staining seen (Fig. 1D), proving that these two receptors are expressed at a similar level at the cell surface and implicating poor recognition of KIR3DS1 by Z27 in the observed low-intensity staining.

D1 residues differentially contribute to the DX9 and Z27 epitope

We next examined the role of the D1 amino acid residues in controlling Ab affinity by mutating these amino acid residues in *01502 to the corresponding amino acid found in *054 and 3DS1 using the primers outlined in Table I. Protein levels were titrated...
by transfection of HEK293T cells with increasing concentration of DNA. Mutation of *01502 at a single residue 138 (glycine to tryptophan, G138W) dramatically reduces recognition by both DX9 and Z27 Abs (Fig. 2A), implicating this residue in the epitope recognized by both Ab clones. The intensity of staining was still greater than that seen with the *054 allotype suggesting that while position 138 plays an important role in the formation of the binding face, position 163, 166, or 238 also contributes to the binding. Indeed, the combined mutation of residues 163 and 166 also caused a reduction in the affinity of both Abs for *01502 (data not shown). When we examined the role of 136 and 166 individually, we found that mutation of 166 had a profound effect on the recognition by DX9 but did not appear to contribute substantially to the Z27 epitope (Fig. 2B). Single mutation of the residue at position 163 did not influence binding of either Ab. All mutant constructs were carefully analyzed for evidence of intracellular retention/variation in levels of cell surface expression using anti-FLAG Ab. We did not see any consistent difference relative to *01502. To reduce the noise due to slight variations in transfection efficiency, we normalized DX9 and Z27 binding intensity relative to the levels of FLAG staining observed. This ratio gives a reflection of the Ab affinity without influence from slight variations in the level of receptor expression.

As mutation of *01502 at residues 138, 166, and 163+166 results in reduced Ab recognition, we wished to examine the role of these amino acids in the binding face of KIR3DS1. These positions were altered in KIR3DS1 to express the residues found in inhibitory KIR3DL1 allotypes. We observed differences in Ab recognition by DX9 and Z27 Abs (Fig. 2C), in the absence of any change in the degree of cell surface expression. Mutation of residue 138 from tryptophan to the glycine residue, which is highly conserved across all KIR receptors (apart from KIR3DS1), results in increased recognition by the Z27 Ab but did not confer recognition by the DX9 Ab. This suggests that this amino acid is an important determinant of the weak reactivity of Z27 seen for 3DS1, but reversion of this position to the common KIR3DL1 residue is not sufficient to allow DX9 recognition. Together with the dramatic loss of DX9 reactivity in the reciprocal mutation of *01502 (*01502 G138W, Fig. 2A), these data suggest that whereas the presence of glycine at position 138 is necessary for strong DX9 recognition, it is not sufficient. In contrast, substitution at position 166 resulted in recognition (albeit weak) by DX9 but did not significantly affect the affinity of Z27 Ab (Fig. 2C), demonstrating the independent effects of these two positions on DX9 and Z27 reactivity. As KIR3DS1 and several revertants do not show any affinity for the DX9 Ab, regardless of good cell surface expression, the DX9 mean fluorescence intensity (MFI) expressed relative to FLAG drops to less than one.

Position 199 contributes to the Z27 epitope

KIR3DS1 also contains a unique amino acid at position 199 in the D2 domain, expressing a leucine in place of a proline residue. Mutation of this residue in KIR3DS1 does not alter either cell surface expression or DX9 reactivity but did abrogate recognition by the Z27 Ab (Fig. 2D). This result is somewhat unexpected as Z27 shows greater affinity for inhibitory allotypes (expressing a proline at this position) than for KIR3DS1. However, in the context of the KIR3DS1 sequence, the presence of proline at this position completely abrogated recognition, suggesting that the exact nature of the epitope recognized by Z27 differs between inhibiting and activating forms of this 3D KIR. Indeed, when the sequence was further altered to more closely resemble the sequence in inhibitory allotypes, with residue 138 also reverted, Z27 recognition was restored to a level greater than that seen with native KIR3DS1 sequence but less than that seen with single mutation of position 138 (Fig. 2D). The double 138+199 variant was also recognized by DX9, showing that whereas substitution at either 138 or 199 alone was not sufficient to generate a protein recognized by DX9, the combination of these two positions results in Ab recognition. Notably, the *054 allotype, which is identical to KIR3DS1 in the D1 domain (including W138) but contains a proline at position 199, is recognized, albeit weakly, by DX9. *054 differs from KIR3DS1 at several positions both in the D0 and D2 domains, implicating at least one of these residues in the generation of the DX9 epitope.

Single amino acid substitutions in D1 of KIR3DL1 abrogate HLA binding

HLA-Bw4 binding has been detected with all tested inhibitory KIR3DL1 subtypes; binding to KIR3DS1, however, cannot be observed under similar conditions. This mirrors the reactivity seen with the DX9 Ab suggesting that the key amino acids involved in

Table I. Mutagenesis primers: primer sequences used for the mutagenesis of KIR3DL1 and KIR3DS1 constructs

<table>
<thead>
<tr>
<th>KIR Allotype</th>
<th>Amino Acid</th>
<th>Nucleotide</th>
<th>Primer Sequence (Forward and Reverse)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>KIR3DL1*01502</td>
<td>G138W</td>
<td>G475T</td>
<td>CTGCACAAAAAGAGCTCCTAGGACCC</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>GGGTCTTACGATACCTCCTTTGAGG</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>CATGACAAAGGTAAGAGAGG</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>CAATTTCTCCATCGGTCCCATGATGCTTGCCC</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>CGGTCCCATGATGCGTGCCCTTGCAGGG</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>CCCCAGCAAGGCGGACATGCAGGGAG</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>KIR3DS1 W138G</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>CTGCACAAAAAGGAGGCCCTCTAGGACCC</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>GGGTCTTACGATACCTCCTTTGAGG</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>CATGACAAAGGTAAGAGAGG</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>CAATTTCTCCATCGGTCCCATGATGCTTGCCC</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>CGGTCCCATGATGCGTGCCCTTGCAGGG</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>CCCCAGCAAGGCGGACATGCAGGGAG</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>KIR3DL1*01502 G138W</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>CTGCACAAAAAGAGTGTTAGTTCTTAGGACCC</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>GGGTCTTACGATACCTCCTTTGAGG</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>CATGACAAAGGTAAGAGAGG</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>CAATTTCTCCATCGGTCCCATGATGCTTGCCC</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>CGGTCCCATGATGCGTGCCCTTGCAGGG</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>CCCCAGCAAGGCGGACATGCAGGGAG</td>
</tr>
<tr>
<td>KIR3DS1</td>
<td>W138G</td>
<td>T475G</td>
<td>CTGCACAAAAAGGAGGCCCTCTAGGACCC</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>GGGTCTTACGATACCTCCTTTGAGG</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>CATGACAAAGGTAAGAGAGG</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>CAATTTCTCCATCGGTCCCATGATGCTTGCCC</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>CGGTCCCATGATGCGTGCCCTTGCAGGG</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>CCCCAGCAAGGCGGACATGCAGGGAG</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>KIR3DS1 S163P</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>CGGTCCCATGATGCGTGCCCTTGCAGGG</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>CCCCAGCAAGGCGGACATGCAGGGAG</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>KIR3DS1</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>CCCTGCAAGGGCAAGCATGTCAGGG</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>GGGGTCCTTAGAGATCCCTCTTCTC</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>KIR3DS1</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>CCCTGCAAGGGCAAGCATGTCAGGG</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>GGGGTCCTTAGAGATCCCTCTTCTC</td>
</tr>
</tbody>
</table>

*The forward sequence is given in the first row and the reverse sequence in the second row of the respective table cell for each primer.
both Ab and HLA recognition are the same. To test this possibility,
we examined the ability of 3DL1*01502 constructs to bind to
HLA tetramers, including two HLA-Bw4 tetramers (B*2705 and
A*2402). Expression of 3DL1*01502 in HEK293T cells was
found to lead to binding of Bw4 tetramers (Fig. 3A), which could
be inhibited by blocking with the Z27 Ab (data not shown).

Binding to the Bw6 tetramer B*0801 was used as a negative
control. Substitution at position 138 (G138W) dramatically re-
duced the binding of KIR3DL1 to the tested tetramers (Fig. 3B).
Similarly, mutation of position 166 also resulted in a loss of tet-
ramer binding, whereas single mutation of position 163 resulted in
a loss of binding to B*2705-SRHHAFLFR tetramer but only

---

**FIGURE 1.** Allelic variant *054 is poorly recognized by two anti-3DL1 Abs despite maintained cell surface expression. A, A comparison of selected KIR3DL1 and KIR3DS1 allotypes at key D1 and D2 residues. B, HEK293T cells were transfected with 2 μg of plasmid containing FLAG-tagged KIR3DL1*01502 (left panels) or KIR3DL1*054 (right panels) and stained with anti-FLAG and anti-KIR3DL1 DX9 (top panels) or Z27 (bottom panels) Abs. C, HEK293T cells were transfected with increasing concentrations of plasmid expressing FLAG-tagged KIR3DL1*01502 (closed diamonds) or KIR3DL1*054 (open circles) and stained with anti-FLAG Ab. D, HEK293T cells were transfected with increasing concentrations of plasmid expressing FLAG-tagged KIR3DL1*01502 (closed squares) or KIR3DS1 (closed triangles) and stained with anti-FLAG Ab. MFI of FLAG was calculated by gating on the FLAG-positive cells. The results are representative of findings made in at least two independent experiments.
FIGURE 2. Allelic polymorphism in KIR3DL1 uncovers amino acid variations in D1 domain that differentially influences DX9 and Z27 recognition. A, HEK293T cells were transfected with increasing concentration of plasmid expressing FLAG-tagged KIR3DL1*01502 (squares), KIR3DL1*054 (upright triangle), or KIR3DL1*01502 G138W (inverted triangle) and stained with anti-FLAG, DX9, and Z27 Abs. The MFI of the positive population is shown. B, As for A with plasmids containing FLAG-tagged KIR3DL1*01502 (squares), *01502 P163S (upright triangles), and *01502 L166R (inverted triangles). Data are expressed as DX9 or Z27 MFI relative to the anti-FLAG MFI of the total cell population to normalize for variation in cell surface expression due to transfection efficiency (e.g., for *01502 1 µg DNA: FLAG MFI 26, DX9 MFI 129, ratio 5.0). C, HEK293T cells were transfected with increasing concentration of plasmid expressing FLAG-tagged KIR3DS1 (closed squares), KIR3DS1 W138G (triangle), KIR3DS1 S163P (open squares), KIR3DS1 R166L (inverted triangle), and KIR3DS1 L199P (open circle).
reduced the binding to A*2402-RYPLTFGW. Thus, it appears that all three D1 residues that differ between KIR3DL1 and KIR3DS1 play a role in HLA recognition. As KIR3DL1*054 contains all three of these substitutions (G138W, P163S, L166R), we predicted that this allotype would not recognize HLA-Bw4, and indeed binding to HLA-B*5701 was lost (data not shown).

**FIGURE 3.** Single amino acid substitutions in the D1 domain of KIR3DL1 abrogate HLA binding. A, HEK293T cells were transfected with 2 μg of plasmid containing FLAG-tagged KIR3DL1*01502, *01502 G138W, *01502 P163S, and *01502 L166R and stained with PE-conjugated HLA tetramers. Dashed line represents staining with HLA-A*2402 (left panels) or HLA-B*2705 (right panels), and solid line represents staining with control HLA-B*0801. B, The MFI of the tetramer-stained cells is expressed as fold change over the fluorescence of unstained cells. Data shown are the averages of two independent experiments; error bars represent SD.

**Single amino acid reversion of position 138 of KIR3DS1 permits HLA binding**

Mutation of *01502 suggests that all three 3DS1-specific D1 positions contribute to HLA binding, in particular positions 138 and 166. To examine the influence of these amino acid positions in the context of the KIR3DS1 sequence, we expressed KIR3DS1 and single mutants in HEK293T cells and examined HLA reactivity. Despite the evidence from KIR3DL1 that the presence of glycine at position 138 and leucine at position 166 was necessary for HLA recognition (Fig. 3), we found that KIR3DS1 with a single substitution at position 138 was sufficient to confer HLA binding. This binding is seen with both HLA-Bw4 tetramers A*24 and B*57, but specificity for HLA-Bw4 is maintained, as no binding to the HLA-Bw6 tetramer B*08 was detected (Fig. 4A). KIR3DS1 transfectants did not bind to any of the tested tetramers (data not shown). The binding to both HLA-A*24 and HLA-B*57 could be blocked by preincubation with the Z27 Ab. Single reversion of either 163 or 166 in KIR3DS1 was not sufficient to allow tetramer binding (data not shown).
To confirm the recognition of HLA-Bw4 by KIR3DS1 W138G, we tested the interaction using a chimeric reporter assay. Jurkat cells stably expressing KIR3DS1 or KIR3DS1 W138G as chimeric receptors with CD3z-chain were stimulated with 721.221 cell lines expressing HLA-B*5701 or HLA-B*5801 (both Bw480I allotypes). Although both KIR3DS1 cell lines responded with a clear increase in NFAT upon stimulation with plate-bound Z27 Ab, only KIR3DS1 W138G showed recognition of HLA-Bw4 (Fig. 4B).

Complex interaction of 3DS1-specific residues combine to control HLA recognition

Mutation of position 138 in KIR3DS1 (tryptophan to glycine) resulted in increased affinity of the Z27 Ab; however, reverting both 138 and 199 together reduced the affinity back to baseline (Fig. 2D). This suggests that the interaction of these amino acid residues in the D1 and D2 domains of the protein determine Ab reactivity, at least in part. To address the possibility that this was also true for HLA binding, we generated a panel of KIR3DS1 mutations in which combinations of positions 138, 163, 166, and 199 were reverted to the residue found in KIR3DL1. These constructs were transfected into the HEK293T cells, and their ability to bind Bw4 tetramers was examined as before. Reversion of W138G alone was sufficient to allow tetramer binding, and combining this with reversion of position 166 (arginine to leucine) gave similar levels of binding (Fig. 5A). The combination of 138 and 163 resulted in increased tetramer staining, despite the dominant role of position 166 in KIR3DL1 binding. Notably, when reversion of position 138 was combined with position 199 (leucine to proline), HLA reactivity was lost (Fig. 5A). Triple revertants of 138+199 with either 163 or 166 similarly gave no HLA reactivity. Only when all the residues in the cluster were reverted to the KIR3DL1 sequence was HLA binding restored in the presence of proline 199 (Fig. 5B).

Discussion

KIR3DL1 is a highly polymorphic KIR with greater than 60 alleles described to date. Allotypic variation is known to influence the pattern of Ab reactivity, HLA-Bw4 binding characteristics, and peptide specificity of these KIR3DL1 variants. The KIR3DL1 allele *054 is identical to the common *002 allele at all positions except those in exon 4, where it is identical to KIR3DS1. This new allele is likely to have arisen by a gene conversion event where exon swapping between an existing KIR3DL1 allele (*002) and KIR3DS1 occurred. In our previous study, we identified this allele in only one person of Hispanic origin (2), and there are no additional reports in the ImMunoGeneTics database. We have previously shown that NK cells from a *054 donor display a very-low-intensity staining profile with an anti-KIR3DL1 Ab, which suggested that this allotype may be expressed at a low level on the cell surface, possibly due to intracellular retention as has been...
shown for other allotypes (2). However, we have shown in this study that the *054 allotype is well expressed at the cell surface and that the dim staining profile is a reflection of reduced Ab affinity. This is similar to the poor recognition by Z27 of KIR3DS1, which our findings in this study show is also well expressed at the cell surface. Much of the reduced recognition of *054 relative to *01502 is due to the dramatic amino acid change at position 138, from the small glycine residue to the bulky tryptophan, which considerably reduced the affinity of both Ab clones. Although the staining pattern of DX9 mirrors that of Z27 for inhibitory KIR3DL1 allotypes, it has been appreciated that the exact epitopes for these two Abs differ with mutation at residue 200 playing a role in the DX9 but not the Z27 recognition (30). In this study, we identify a role for position 138 in both Ab epitopes, whereas DX9 is more heavily dependent on position 166 and Z27 on position 163. Sharma et al. (25) reported similar results for the role of positions 163 and 166 in a mutagenesis study of KIR3DL1*015 but failed to detect any effect of position 138. Although this discrepancy is puzzling, the role of position 138 in both the DX9 and Z27 epitope is further supported in the analysis of 3DS1 mutants in which single residues were reverted to those found in KIR3DL1 allotypes. Notably, although in the context of KIR3DS1 positions 138 and 199 cooperate to form a DX9 epitope, the double revertant showed weaker Z27 staining than that seen with the single 138. This is surprising given that KIR3DL1 allotypes that are well recognized by Z27 have these residues at positions 138 and 199, highlighting the role of positions 163 and 166 in the formation of the binding face. Thus the variation among donors in the profile of Ab staining of KIR3DL1 is attributable to allelic polymorphism leading to variation in the frequency of gene expression (31), mature protein at the cell surface (26, 27), as well as variation in Ab affinity.

In addition to the difference seen between KIR3DL1 and KIR3DS1 in Ab affinity, the more relevant difference in these molecules is the lack of HLA binding to KIR3DS1. Our analysis of KIR3DL1*01502 suggests that, similar to the DX9 epitope, the key residues involved in HLA recognition are 138 and 166, with a lesser role for 163. Single mutation of either 138 or 166 completely abrogated binding to two different Bw4 tetramers, and mutation of position 163 led to the loss of binding to B*2705 and a reduction in A*2402 binding. The critical individual role of these multiple D1 variants suggests that the rare KIR3DL1 allotype *054, which varies from all other 3DL1 allotypes at these three positions, would not be capable of binding HLA-Bw4. Indeed, this proved to be the case, as no binding was detectable to HLA-B*57 tetramer (data not shown). This rare allotype is likely to represent a recently arisen variant of KIR3DL1, generated via an exon 4 swap with KIR3DS1 that shares with KIR3DS1 a lack of broad HLA-Bw4 reactivity. It differs from KIR3DS1 in the potential HLA binding face in possessing proline rather than leucine at position 199 (encoded by exon 5). Based on the evidence we present in this article that position 199 cooperates with the residues of D1 to determine HLA binding, we predict that *054 will not share the (as yet undefined) specificity of KIR3DS1. Rather, KIR3DL1*054 may represent a KIR3DL1 allotype with no affinity for HLA-Bw4, although more extensive analysis would be required to confirm this.

Analysis of the D1 dimorphic residues in the context of KIR3DL1 binding to HLA-Bw4 suggests than any one of D1 changes could be responsible for the lack of detectable HLA binding by KIR3DS1. It was therefore unexpected when reversion of position 138 alone in KIR3DS1 allowed binding to HLA. This variant of KIR3DS1 bound to both A*2402 and B*5701 (both Bw4 80I molecules) but not B*2705 (Bw4 80T) tetramer. This is of particular interest because an allotype of KIR3DS1 (3DS1*014) has been described that carries a glycine in place of tryptophan at this position (32, 33). Thus, we have characterized KIR3DS1*014 as an activating 3D receptor with the potential for robust recognition of multiple Bw4 allotypes. Phylogenetic analysis of KIR3DL1 and KIR3DS1 sequences by Norman et al. (33) reveals that the extracellular domains of KIR3DS1 lineage diverged from KIR3DL1 lineages >3.9 million years ago. This analysis suggests that KIR3DS1*014 arose earlier than KIR3DS1*013 and likely represents an intermediate between the ancestral HLA-binding inhibitory receptors and KIR3DS1*013. KIR3DS1*013 was subsequently subject to positive selection and now represents the overwhelming majority of KIR3DS1 sequences globally. This suggests that there was a strong evolutionary pressure to maintain the KIR3DS1*013 allotype with its restricted Bw4 recognition rather than an activating KIR3DS1*014 with broad Bw4 specificity.

KIR3DS1*014 has been reported in only three populations (English, Tanzanian, and Nigerian) and here only at low allele frequency (0.003, 0.006, and 0.003, respectively). Notably, two of these populations are African, which shows a higher frequency of HLA-Bw4 carriage (and in particular HLA-Bw4 80I) (34), which, as we show in this study, acts as a ligand for this receptor. It is therefore attractive to speculate that this activating receptor may have in the past provided a selective advantage in these regions, where, for example, high ligand frequency and unique environment of pathogens may have allowed those individuals with KIR3DS1*014 to mount a more effective immune response. The low frequency of this receptor that is now present in these populations may therefore represent a move toward loss of this activating receptor in the absence of that selective pressure, a feature seen in the evolution of other activating KIRs (discussed later).

The lack of a well-defined ligand for KIR3DS1*013 remains a significant challenge in the field. The ability to detect evidence of an interaction of KIR3DS1 with HLA-Bw4 only in the presence of HIV infection suggests that this recognition may be controlled at the level of peptide presented. Alternatively, factors including the level of HLA class I expression and the presence of additional cofactors or coreceptors may determine the nature of the interaction. Among other members of the KIR family, KIR3DL2 shows a strong dependence on the presented peptide, with binding to A*03 and A*11 appearing to rely on the presence of EBV-derived sequences (6). The interaction of KIR2DS1 with HLA-C2 is influenced by the level of HLA expression, with binding seen only after an increase in expression as a consequence of EBV infection (9).

The low-affinity interaction of the KIR2DS molecules with their HLA-C ligands has been mapped to specific amino acid residues in the extracellular domain that differ from those found in the inhibitory counterparts. For KIR2DS1, this difference in binding affinity was mapped to position 70 of the KIR molecule, with substitution of the threonine of 2DL1 for the lysine of 2DS1 diminishing the binding of the long-tailed KIR (35). Similarly, the binding of 2DS2 to HLA-C is of much lower affinity than that of the corresponding inhibitory KIR (2DL2/3). This receptor differs from KIR2DL2/3 by only 4 aa in the extracellular domain—substitution at position 45 (a tyrosine in 2DS2) for phenylalanine was found to enhance the affinity of the 2DS KIR for HLA-C ligand (10, 11). The restriction of HLA binding of KIR2DS4 (which recognizes some C1 and C2 allotypes as well as A*11) has been attributed to a gene conversion event with KIR3DL2 that resulted in a reduction of affinity of the parental molecule for HLA-C (36). Thus, it appears that a common event in the evolution of the activating KIRs from their older inhibitory counterparts...
is the introduction of specific amino acid changes that result in a reduction in affinity for HLA. In contrast, for KIR3DS1 there are at least 4 aa changes, over two different exons, which could be responsible for the lack of broad HLA binding by KIR3DS1. Although analysis of single changes to the *01502 protein suggests that any one of these changes could be responsible for the “tuning down” of KIR3DS1 binding, the presence of additional variant positions that impact HLA recognition suggests that the driving force by which KIR3DS1 was generated from KIR3DL1 may differ from that of the HLA-C recognizing 2D KIR. Studies of KIR3DS1 revertants in which combinations of two or more of these variant positions are mutated suggest that the role of individual amino acids in the recognition of HLA by KIR3DS1 may also differ from KIR3DL1. Thus, whereas proline at 199 appears to be necessary for KIR3DL1 recognition of HLA (25), it prevents HLA binding by KIR3DS1 with 183G mutants. One intriguing interpretation of these data is that the HLA recognition by KIR3DS1 does not simply mirror that of KIR3DL1 but with lower affinity, as is the case of KIR2DS1 and KIR2DS2. Rather, the additional amino acid changes may reflect a reprogramming or restriction of the affinity for HLA-Bw4 thereby limiting reactivity. Analysis of the evolution of activating KIRs from their inhibitory KIRs suggests that this is a recurrent process with cycles of gain and loss in the absence of a strong, persistent evolutionary pressure to maintain activating KIRs (37). This is consistent with data from disease association studies that suggest a protective role of activa-

The authors have no financial conflicts of interest.

Disclosures

The authors have no financial conflicts of interest.

References


Acknowledgments

We thank Drs. Peter Parham and Galit Alter for the generous gift of reagents. We are grateful to Kathleen Noer and Roberta Matthai for cell sorting. We also thank Dr. Colm O’hUigin for critical reading of the manuscript.

Downloaded from http://www.jimmunol.org/ by guest on April 14, 2017